

1. DATE ISSUED MM/DD/YYYY 09/10/2019		1a. SUPERSEDES AWARD NOTICE dated except that any additions or restrictions previously imposed remain in effect unless specifically rescinded	
2. CFDA NO. 93.118 - Acquired Immunodeficiency Syndrome (AIDS) Activity			
3. ASSISTANCE TYPE Cooperative Agreement			
4. GRANT NO. 1 NU65PS923714-01-00 Formerly		5. TYPE OF AWARD Other	
4a. FAIN NU65PS923714		5a. ACTION TYPE New	
6. PROJECT PERIOD MM/DD/YYYY From 09/30/2019		Through 09/29/2020	
7. BUDGET PERIOD MM/DD/YYYY From 09/30/2019		Through 09/29/2020	
8. TITLE OF PROJECT (OR PROGRAM) Strategic Partnerships and Planning to Support Ending the HIV Epidemic in the United States			

**DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
CDC Office of Financial Resources**

2939 Brandywine Road
Atlanta, GA 30341

NOTICE OF AWARD
AUTHORIZATION (Legislation/Regulations)
[AWARD AUTHORITY NOT DEFINED FOR PS10-10136.NU2G]

9a. GRANTEE NAME AND ADDRESS HEALTH AND SENIOR SERVICES, MISSOURI DEPARTMENT OF 920 Wildwood Dr Jefferson City, MO 65109-5796		9b. GRANTEE PROJECT DIRECTOR Ms. Christine Smith 920 Wildwood Drive Jefferson City, MO 65109-5796 Phone: 573-751-6439	
10a. GRANTEE AUTHORIZING OFFICIAL Ms. Tonya R Loucks 920 Wildwood Drive Jefferson City, MO 65109-5796 Phone: 573-751-6014		10b. FEDERAL PROJECT OFFICER Mary Allen 1600 Clifton Rd Atlanta, GA 30333 Phone: 404-639-5200	

ALL AMOUNTS ARE SHOWN IN USD

11. APPROVED BUDGET (Excludes Direct Assistance)				12. AWARD COMPUTATION			
I Financial Assistance from the Federal Awarding Agency Only				a. Amount of Federal Financial Assistance (from item 11m) 322,072.00			
II Total project costs including grant funds and all other financial participation <input type="checkbox"/> I				b. Less Unobligated Balance From Prior Budget Periods 0.00			
a. Salaries and WageS 42,289.00				c. Less Cumulative Prior Award(s) This Budget Period 0.00			
b. Fringe Benefits 23,682.00				d. AMOUNT OF FINANCIAL ASSISTANCE THIS ACTION 322,072.00			
c. Total Personnel Costs 65,971.00				13. Total Federal Funds Awarded to Date for Project Period 322,072.00			
d. Equipment 0.00				14. RECOMMENDED FUTURE SUPPORT			
e. Supplies 1,500.00				(Subject to the availability of funds and satisfactory progress of the project):			
f. Travel 23,685.00				YEAR TOTAL DIRECT COSTS YEAR TOTAL DIRECT COSTS			
g. Construction 0.00				a. 2 b. 3 c. 4 d. 5 e. 6 f. 7			
h. Other 1,798.00				15. PROGRAM INCOME SHALL BE USED IN ACCORD WITH ONE OF THE FOLLOWING ALTERNATIVES:			
i. Contractual 215,000.00				a. DEDUCTION			
j. TOTAL DIRECT COSTS → 307,954.00				b. ADDITIONAL COSTS			
k. INDIRECT COSTS 14,118.00				c. MATCHING			
l. TOTAL APPROVED BUDGET 322,072.00				d. OTHER RESEARCH (Add / Deduct Option)			
m. Federal Share 322,072.00				e. OTHER (See REMARKS)			
n. Non-Federal Share 0.00				16. THIS AWARD IS BASED ON AN APPLICATION SUBMITTED TO, AND AS APPROVED BY, THE FEDERAL AWARING AGENCY ON THE ABOVE TITLED PROJECT AND IS SUBJECT TO THE TERMS AND CONDITIONS INCORPORATED EITHER DIRECTLY OR BY REFERENCE IN THE FOLLOWING:			
				a. The grant program legislation			
				b. The grant program regulations.			
				c. This award notice including terms and conditions, if any, noted below under REMARKS.			
				d. Federal administrative requirements, cost principles and audit requirements applicable to this grant.			
				In the event there are conflicting or otherwise inconsistent policies applicable to the grant, the above order of precedence shall prevail. Acceptance of the grant terms and conditions is acknowledged by the grantee when funds are drawn or otherwise obtained from the grant payment system.			

REMARKS (Other Terms and Conditions Attached - Yes No)
New Award: Financial Assistance in the amount of \$322,072

GRANTS MANAGEMENT OFFICIAL:

Arthur Lusby, Grants Management Officer, Team Lead
2960 Brandywine Rd
Mailstop E15
Atlanta, GA 30341-5509
Phone: 770.488.2865

17.OBJ CLASS 41.51	18a. VENDOR CODE	18b. EIN	19. DUNS 878092600	20. CONG. DIST. 03
FY-ACCOUNT NO.	DOCUMENT NO.	ADMINISTRATIVE CODE	AMT ACTION FIN ASST	APPROPRIATION
21. a. 9-9390D7H	b. 19NU65PS923714	c. PS	d. \$322,072.00	e. 75-19-0120
22. a.	b.	c.	d.	e.
23. a.	b.	c.	d.	e.

NOTICE OF AWARD (Continuation Sheet)

PAGE 2 of 3	DATE ISSUED 09/10/2019
GRANT NO. 1 NU65PS923714-01-00	

Direct Assistance

BUDGET CATEGORIES	PREVIOUS AMOUNT (A)	AMOUNT THIS ACTION (B)	TOTAL (A + B)
Personnel	\$0.00	\$0.00	\$0.00
Fringe Benefits	\$0.00	\$0.00	\$0.00
Travel	\$0.00	\$0.00	\$0.00
Equipment	\$0.00	\$0.00	\$0.00
Supplies	\$0.00	\$0.00	\$0.00
Contractual	\$0.00	\$0.00	\$0.00
Construction	\$0.00	\$0.00	\$0.00
Other	\$0.00	\$0.00	\$0.00
Total	\$0.00	\$0.00	\$0.00

NOTICE OF AWARD (Continuation Sheet)

PAGE 3 of 3	DATE ISSUED 09/10/2019
GRANT NO. 1 NU65PS923714-01-00	

Federal Financial Report Cycle			
Reporting Period Start Date	Reporting Period End Date	Reporting Type	Reporting Period Due Date
09/30/2019	09/29/2020	Annual	12/28/2020

AWARD ATTACHMENTS

Missouri Department of Health

1 NU65PS923714-01-00

1. Terms and Conditions

Notice of Funding Opportunity Announcement (NOFO): CDC-RFA-PS19-1906

Award Number: 1 NU65PS923714-01

Award Type: Cooperative Agreement

Applicable Regulations: 45 Code of Federal Regulations (CFR) Part 75, Uniform Administrative Requirements, Cost Principles, and Audit Requirements for HHS Awards

AWARD INFORMATION

Incorporation: In addition to the federal laws, regulations, policies, and CDC General Terms and Conditions for Non-research awards at <https://www.cdc.gov/grants/federalregulationspolicies/index.html>, the Centers for Disease Control and Prevention (CDC) hereby incorporates Notice of Funding Opportunity (NOFO) number **CDC-RFA-PS19-1906**, entitled ***Strategic Partnerships and Planning to Support Ending the HIV Epidemic in the United States***, dated, **July 12, 2019**, as may be amended, which are hereby made a part of this Non-research award, hereinafter referred to as the Notice of Award (NoA).

Approved Funding: Funding in the amount of **\$307,954** is approved for **Component B** for the **Year 01** budget period, which is **September 30, 2019** through **September 29, 2020**. All future year funding will be based on satisfactory programmatic progress and the availability of funds.

The federal award amount is subject to adjustment based on total allowable costs incurred and/or the value of any third-party in-kind contribution when applicable.

Note: Refer to the Payment Information section for Payment Management System (PMS) subaccount information.

Financial Assistance Mechanism: Cooperative Agreement

Substantial Involvement by CDC: This is a cooperative agreement and CDC will have substantial programmatic involvement after the award is made. Substantial involvement is in addition to all post-award monitoring, technical assistance, and performance reviews undertaken in the normal course of stewardship of federal funds.

CDC program staff will assist, coordinate, or participate in carrying out effort under the award, and recipients agree to the responsibilities therein, as detailed in the NOFO.

1. Provide guidance and coordination to funded organizations to improve the quality and effectiveness of work plans, evaluation strategies, products and services, and collaborative activities with other organizations.
2. Collaborate to ensure coordination and provide policy and program information for rapid dissemination and implementation.
3. Work with recipients to identify and address capacity building assistance (CBA) and TA needs that are essential to the success of the project.
4. Provide access to training and TA that will strengthen staff capacity relevant to all required strategies and activities of the program.
5. Provide guidance to the recipient and set standards on data collection, use, and submission requirements.
6. Provide guidance to the recipient and set standards on data collection, use, and submission requirements.
7. Provide technical advice in the development of systems to implement and advance CDC policies, initiatives and programs.
8. Collaborate to ensure coordination and implementation of technical assistance services to state and local health department HIV program staff.
9. Collaborate in assessing progress toward meeting goals/outcomes and in establishing measurement and accountability systems for documenting outcomes, such as increased performance improvements and

- best or promising practices
10. Provide guidance and coordinate with the recipient to improve the quality and effectiveness of the proposed program. This may include revision of the work plan, evaluation strategy, products and services, among others.
 11. Foster and support ongoing opportunities for networking, communication, coordination, and collaboration.
 12. Provide consultation in planning, operating, analyzing and evaluating HIV surveillance and prevention programs, including HIV prevention planning, CDC special initiatives, (e.g., program integration, comprehensive HIV prevention programs, and program evaluation activities.)
 13. Monitor recipient program performance using multiple approaches, such as standardized review of performance, recipient feedback and other data reports, to support program development, implementation, evaluation, and improvement.
 14. Provide support and facilitate program collaboration with other CDC programs and HHS offices to enhance and improve integration of services.
 15. Assist in assessing program operations and in evaluating overall effectiveness of programs.
 16. Provide capacity building assistance where identified or as needed to the recipient.
 17. Collect and disseminate information, best practices, lessons learned, and evaluation results (e.g., through conferences, guidance, material development, webinars, data sharing publications, other social media, participation in meetings, committees, and working groups related to the cooperative agreement).
 18. Provide requirements and expectations for standardized and other data reporting and support monitoring and evaluation activities.

Technical Review Response Requirement: The review comments on the strengths and weaknesses of the proposal are provided as a part of this award and are in **GrantSolutions in “Correspondence”**. A response to the weaknesses in these statements must be uploaded for approval **into GrantSolutions as a “Grant Note”** no later than 30 days from the budget period start date. Provide the award number in the subject line. Failure to submit the required information by the due date, **October 30, 2019**, will cause delay in programmatic progress and will adversely affect the future funding of this project.

Budget Revision Requirement: By **October 30, 2019**, the recipient must submit a revised budget with a Narrative justification and work plan. Failure to submit the required information in a timely manner may adversely affect future funding of this project. If the information cannot be provided by the due date, you are required to contact the GMS/GMO identified in the Staff Contacts section of this notice before the due date. The Budget Revision is a prior approval submitted in **Grant Solutions** as an **amendment**.

Key Personnel: In accordance with 45 CFR Part 75.308, CDC recipients must obtain prior approval from CDC for (1) change in the project director/principal investigator, business official, authorized organizational representative or other key persons specified in the NOFO, application or award document; and (2) the disengagement from the project for more than three months, or a 25 percent reduction in time devoted to the project, by the approved project director or principal investigator

Program Income: Any program income generated under this grant or cooperative agreement will be used in accordance with the **Addition** alternative.

Addition alternative: Under this alternative, program income is added to the funds committed to the project/program and is used to further eligible project/program objectives.

Note: The disposition of program income must have written prior approval from the GMO.

FUNDING RESTRICTIONS AND LIMITATIONS

Notice of Funding Opportunity (NOFO) Restrictions:

- Recipients may not use funds for clinical care except as allowed by law.
- Recipients may use funds only for reasonable program purposes, including personnel, travel, supplies, and services.
- Generally, recipients may not use funds to purchase furniture or equipment. Any such proposed spending must be clearly identified in the budget.
- Reimbursement of pre-award costs generally is not allowed, unless the CDC provides written approval to the recipient.
- Other than for normal and recognized executive-legislative relationships, no funds may be used for:
 - o publicity or propaganda purposes, for the preparation, distribution, or use of any material designed to support or defeat the enactment of legislation before any legislative body
 - o the salary or expenses of any grant or contract recipient, or agent acting for such recipient, related to any activity designed to influence the enactment of legislation, appropriations, regulation, administrative action, or Executive order proposed or pending *before any legislative body*
- See Additional Requirement (AR) 12 (<http://www.cdc.gov/grants/additionalrequirements/index.html#ar12>) for detailed guidance on this prohibition and additional guidance on lobbying for CDC recipients (http://www.cdc.gov/grants/documents/Anti-Lobbying_Restrictions_for_CDC_Grantees_July_2012.pdf).
- The direct and primary recipient in a cooperative agreement program must perform a substantial role in carrying out project outcomes and not merely serve as a conduit for an award to another party or provider who is ineligible.
- In accordance with the United States Protecting Life in Global Health Assistance policy, all non-governmental organization (NGO) applicants acknowledge that foreign NGOs that receive funds provided through this award, either as a prime recipient or subrecipient, are strictly prohibited, regardless of the source of funds, from performing abortions as a method of family planning or engaging in any activity that promotes abortion as a method of family planning, or to provide financial support to any other foreign non-governmental organization that conducts such activities. See Additional Requirement (AR) 35 for applicability (<https://www.cdc.gov/grants/additionalrequirements/ar-35.html>).

Indirect Costs: Indirect cost in the amount of **\$14,118** is **restricted** and cannot be spent until a current indirect cost rate agreement reflecting the proposed rate for the period **09/30/2018** through **09/29/2019** is submitted to and approved, in writing, by the Grants Management Officer. If the information is not provided by the end of the budget period, the above amount must be reported on the Federal Financial Report as unobligated funds.

REPORTING REQUIREMENTS

Federal Financial Report (FFR, SF-425): The Annual Federal Financial Report (FFR) SF-425 is required and must be submitted to your GMS/GMO no later than 90 days after the end of the budget period. To submit the FFR, login to www.grantsolutions.gov, select “Reports” from the menu bar and then click on Federal Financial Reports.

The FFR for this budget period is due by **December 28, 2020**. Reporting timeframe is **September 30, 2019** through **September 29, 2020**. The FFR should only include those funds authorized and disbursed during the timeframe covered by the report.

Failure to submit the required information in a timely manner may adversely affect the future funding of this project. If the information cannot be provided by the due date, the recipient is required to contact the Grants Officer listed in the contacts section of this notice before the due date.

Final Performance Progress Reporting: The Annual Performance Progress and Monitoring Report (is due no later than 90 days prior to the end of the budget period, **December 28, 2020**, and serves as the continuation application for the follow-on budget period. This report should include the information specified in the solicitation from the GMS/GMO via www.grantsolutions.gov

Performance information collection initiated under this grant/cooperative agreement has been approved by the Office of Management and Budget under **OMB Number 0920-1132, "Performance Progress and Monitoring Report, Expiration Date 8/31/2019.**

Required Disclosures for Federal Awardee Performance and Integrity Information System (FAPIS): Consistent with 45 CFR 75.113, applicants and recipients must disclose in a timely manner, in writing to the CDC, with a copy to the HHS Office of Inspector General (OIG), all information related to violations of federal criminal law involving fraud, bribery, or gratuity violations potentially affecting the federal award. Subrecipients must disclose, in a timely manner in writing to the prime recipient (pass through entity) and the HHS OIG, all information related to violations of federal criminal law involving fraud, bribery, or gratuity violations potentially affecting the federal award. Disclosures must be sent in writing to the CDC and to the HHS OIG at the following addresses:

CDC, Office of Grants Services

Rhonda Burton, Grants Management Specialist (GMS)
Centers for Disease Control and Prevention
Infectious Disease Services Branch 2920
Brandywine Road, TV-2
Atlanta, GA 30341
Telephone: 770-488-1381
Email: bgr2@cdc.gov

AND

U.S. Department of Health and Human Services
Office of the Inspector General
ATTN: Mandatory Grant Disclosures, Intake Coordinator
330 Independence Avenue, SW
Cohen Building, Room 5527
Washington, DC 20201
Fax: (202)-205-0604 (Include "Mandatory Grant Disclosures" in subject line) or
Email: MandatoryRecipientDisclosures@oig.hhs.gov

Recipients must include this mandatory disclosure requirement in all subawards and contracts under this award.

Failure to make required disclosures can result in any of the remedies described in 45 CFR 75.371. Remedies for noncompliance, including suspension or debarment (See 2 CFR parts 180 and 376, and 31 U.S.C. 3321).

CDC is required to report any termination of a federal award prior to the end of the period of performance due to material failure to comply with the terms and conditions of this award in the OMB-designated integrity and performance system accessible through SAM (currently FAPIS). (45 CFR 75.372(b)) CDC must also notify the recipient if the federal award is terminated for failure to comply with the federal statutes, regulations, or terms and conditions of the federal award. (45 CFR 75.373(b))

HIV Program Review Panel Requirement: All written materials, audiovisual materials, pictorials, questionnaires, survey instruments, websites, educational curricula and other relevant program materials must be reviewed and approved by an established program review panel. A list of reviewed materials and approval dates must be submitted to the CDC Grants Management Specialist identified in the CDC Roles and Responsibilities section of this NoA.

PAYMENT INFORMATION

The HHS Office of the Inspector General (OIG) maintains a toll-free number (1-800-HHS-TIPS [1-800-447-8477]) for receiving information concerning fraud, waste, or abuse under grants and cooperative agreements. Information also may be submitted by e-mail to hhstips@oig.hhs.gov or by mail to Office of the Inspector General, Department of Health and Human Services, Attn: HOTLINE, 330 Independence Ave., SW, Washington DC 20201. Such reports are treated as sensitive material and submitters may decline to give their names if they choose to remain anonymous.

Payment Management System Subaccount: Funds awarded in support of approved activities have been obligated in a newly established subaccount in the PMS, herein identified as the “P Account”. Funds must be used in support of approved activities in the FOA and the approved application. All award funds must be tracked and reported separately.

The grant document number (below) must be known in order to draw down funds from this P Account.

Document Number: 19NU65PS2019002419

CDC Staff Contacts

Grants Management Specialist: The GMS is the federal staff member responsible for the day-to-day management of grants and cooperative agreements. The GMS is the primary contact of recipients for business and administrative matters pertinent to grant awards. The GMS, on behalf of the GMO, perform many of the functions described in the GMO section.

GMS Contact:

Rhonda Burton, Grants Management Specialist (GMS)
Centers for Disease Control and Prevention
Infectious Disease Services Branch
2939 Flowers Road TV-2
Atlanta, GA 30341
Telephone: 770-488-1381
Email: bgr2@cdc.gov

Program/Project Officer: The PO is the federal official responsible for monitoring the programmatic, scientific, and/or technical aspects of grants and cooperative agreements, as well as contributing to the effort of the award under cooperative agreements.

Programmatic Contact:

**The Project Officer’s information can be found on page 1 of this Notice of Award.*

Grants Management Officer: The GMO is the federal official responsible for the business and other non-programmatic aspects of grant awards. The GMO is the only official authorized to obligate federal funds and is responsible for signing the NoA, including revisions to the NoA that change the terms and conditions. The GMO serves as the counterpart to the business officer of the recipient organization.

GMO Contact:

Arthur C. Lusby, Grants Management Officer

Centers for Disease Control and Prevention

Office of Grants Services

2939 Flowers Rd, TV-2

Atlanta, GA 30341-4146

Phone: (770) 488-2865

Email: ALusby@cdc.gov